U.S., Feb. 19 -- ClinicalTrials.gov registry received information related to the study (NCT07417917) titled 'QLS12010 Capsules in Adults With Moderate to Severe Hidradenitis Suppurativa' on Feb. 11.
Brief Summary: This is a Phase II clinical study to evaluate the safety, efficacy, pharmacokinetics and pharmacodynamics of QLS12010 capsules in the treatment of moderate to severe Hidradenitis Suppurativa (HS). The study is comprised of two parts: Part A is a multi-center, open-label, single-dose group proof-of-concept study; Part B is a randomized, double-blind, placebo-controlled dose-ranging study. The overall duration of this study is up to 32 weeks, inclusive of the Screening Period, Treatment Period of up to 24 weeks, and the 4-Week Foll...